Last reviewed · How we verify

Neulasta — Competitive Intelligence Brief

Neulasta (PEGFILGRASTIM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukocyte Growth Factor [EPC]. Area: Hematology.

marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor Hematology Recombinant protein Live · refreshed every 30 min

Target snapshot

Neulasta (PEGFILGRASTIM) — Amgen. Neulasta stimulates the production of white blood cells by binding to their receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Neulasta TARGET PEGFILGRASTIM Amgen marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor 2002-01-01
Rolvedon EFLAPEGRASTIM Spectrum Pharms marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor 2022-01-01
Lonquex LIPEGFILGRASTIM Sicor Biotech UAB marketed Granulocyte colony-stimulating factor receptor 2013-01-01
Neupogen Filgrastim-Aafi Amgen marketed Colony-stimulating factor (CSF); leukocyte growth factor G-CSF receptor (granulocyte colony-stimulating factor receptor) 1991-01-01
ROLVEDON EFLAPEGRASTIM-XNST SPECTRUM PHARMS marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor
Neulasta Neulasta Columbia University marketed Granulocyte colony-stimulating factor receptor
FULPHILA PEGFILGRASTIM-JMDB MYLAN GMBH marketed Leukocyte Growth Factor [EPC] Granulocyte colony-stimulating factor receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukocyte Growth Factor [EPC] class)

  1. KASHIV BIOSCIENCES LLC · 2 drugs in this class
  2. Amgen · 1 drug in this class
  3. Berlex Labs · 1 drug in this class
  4. EVIVE BIOTECHNOLOGY · 1 drug in this class
  5. FRESENIUS KABI USA · 1 drug in this class
  6. LUPIN LTD · 1 drug in this class
  7. MYLAN GMBH · 1 drug in this class
  8. SANDOZ INC · 1 drug in this class
  9. SPECTRUM PHARMS · 1 drug in this class
  10. Spectrum Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neulasta — Competitive Intelligence Brief. https://druglandscape.com/ci/pegfilgrastim. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: